Shanghai Haohai Biological Technology (688366.SH) Plans to Acquire 19.8% Stake in Ruiji Biotechnology

Stock News12-12

Shanghai Haohai Biological Technology Co., Ltd. (688366.SH) announced its intention to acquire 8.4661 million shares, representing a 19.8% stake, in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. ("Ruiji Biotechnology") for RMB 38.3515 million in self-raised funds. The shares are currently held by Miao Jiuchang and Miao Chunyun.

Founded in 2002, Ruiji Biotechnology specializes in the production and sales of biological amniotic membranes. Its core products include concave-convex amniotic membrane products, biological orthopedic amniotic membrane products, and wet-state biological amniotic membrane products. These fall under China's Class III medical device category and are primarily used in orthopedic and ophthalmic applications, such as tendon injury repair, ocular surface burn/trauma treatment, and lacrimal duct obstruction support.

The acquisition will grant Haohai distribution rights for Ruiji's products in China, enabling its entry into the high-value biological amniotic membrane medical device sector. This move complements Haohai's existing product portfolio while expanding its presence in ophthalmology and orthopedics.

Additionally, Ruiji's proprietary amniotic membrane materials possess human-derived biological characteristics, which will provide crucial technological and material foundations for Haohai's research and development in regenerative medicine and tissue engineering. This strategic investment is expected to drive future product innovation and technological upgrades.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160204762?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160204762","market":"sg","top_or_hot":-1,"title":"Shanghai Haohai Biological Technology (688366.SH) Plans to Acquire 19.8% Stake in Ruiji Biotechnology","media":"Stock News","content":"<p>Shanghai Haohai Biological Technology Co., Ltd. (688366.SH) announced its intention to acquire 8.4661 million shares, representing a 19.8% stake, in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. (\"Ruiji Biotechnology\") for RMB 38.3515 million in self-raised funds. The shares are currently held by Miao Jiuchang and Miao Chunyun.</p>\n<p>Founded in 2002, Ruiji Biotechnology specializes in the production and sales of biological amniotic membranes. Its core products include concave-convex amniotic membrane products, biological orthopedic amniotic membrane products, and wet-state biological amniotic membrane products. These fall under China's Class III medical device category and are primarily used in orthopedic and ophthalmic applications, such as tendon injury repair, ocular surface burn/trauma treatment, and lacrimal duct obstruction support.</p>\n<p>The acquisition will grant Haohai distribution rights for Ruiji's products in China, enabling its entry into the high-value biological amniotic membrane medical device sector. This move complements Haohai's existing product portfolio while expanding its presence in ophthalmology and orthopedics.</p>\n<p>Additionally, Ruiji's proprietary amniotic membrane materials possess human-derived biological characteristics, which will provide crucial technological and material foundations for Haohai's research and development in regenerative medicine and tissue engineering. This strategic investment is expected to drive future product innovation and technological upgrades.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Haohai Biological Technology (688366.SH) Plans to Acquire 19.8% Stake in Ruiji Biotechnology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Haohai Biological Technology (688366.SH) Plans to Acquire 19.8% Stake in Ruiji Biotechnology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-12 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Haohai Biological Technology Co., Ltd. (688366.SH) announced its intention to acquire 8.4661 million shares, representing a 19.8% stake, in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. (\"Ruiji Biotechnology\") for RMB 38.3515 million in self-raised funds. The shares are currently held by Miao Jiuchang and Miao Chunyun.</p>\n<p>Founded in 2002, Ruiji Biotechnology specializes in the production and sales of biological amniotic membranes. Its core products include concave-convex amniotic membrane products, biological orthopedic amniotic membrane products, and wet-state biological amniotic membrane products. These fall under China's Class III medical device category and are primarily used in orthopedic and ophthalmic applications, such as tendon injury repair, ocular surface burn/trauma treatment, and lacrimal duct obstruction support.</p>\n<p>The acquisition will grant Haohai distribution rights for Ruiji's products in China, enabling its entry into the high-value biological amniotic membrane medical device sector. This move complements Haohai's existing product portfolio while expanding its presence in ophthalmology and orthopedics.</p>\n<p>Additionally, Ruiji's proprietary amniotic membrane materials possess human-derived biological characteristics, which will provide crucial technological and material foundations for Haohai's research and development in regenerative medicine and tissue engineering. This strategic investment is expected to drive future product innovation and technological upgrades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688366","symbol_name":"昊海生科","start_time":0,"source_url":"","article_id":"1160204762","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160204762","pubTimestamp":1765545616,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Haohai Biological Technology Co., Ltd. (688366.SH) announced its intention to acquire 8.4661 million shares, representing a 19.8% stake, in Jiangxi Ruiji Biological Engineering Technology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688366":"昊海生科","BK0239":"医药制造","BK0251":"专用设备"},"translate_title":"上海昊海生物科技（688366.SH）拟收购瑞吉生物19.8%股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688366":1},"content_text":"Shanghai Haohai Biological Technology Co., Ltd. (688366.SH) announced its intention to acquire 8.4661 million shares, representing a 19.8% stake, in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. (\"Ruiji Biotechnology\") for RMB 38.3515 million in self-raised funds. The shares are currently held by Miao Jiuchang and Miao Chunyun.\nFounded in 2002, Ruiji Biotechnology specializes in the production and sales of biological amniotic membranes. Its core products include concave-convex amniotic membrane products, biological orthopedic amniotic membrane products, and wet-state biological amniotic membrane products. These fall under China's Class III medical device category and are primarily used in orthopedic and ophthalmic applications, such as tendon injury repair, ocular surface burn/trauma treatment, and lacrimal duct obstruction support.\nThe acquisition will grant Haohai distribution rights for Ruiji's products in China, enabling its entry into the high-value biological amniotic membrane medical device sector. This move complements Haohai's existing product portfolio while expanding its presence in ophthalmology and orthopedics.\nAdditionally, Ruiji's proprietary amniotic membrane materials possess human-derived biological characteristics, which will provide crucial technological and material foundations for Haohai's research and development in regenerative medicine and tissue engineering. This strategic investment is expected to drive future product innovation and technological upgrades.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160204762","isCrawlerRequest":true}